Topic: Boehringer Ingelheim Gmbh

Boehringer, Vitae partner on Alzheimer's drugs

AP Features - 982 days ago
German drugmaker Boehringer Ingelheim and Vitae Pharmaceuticals say they are partnering to develop enzyme-inhibiting drugs with the potential to slow or even halt progression of Alzheimer's disease.The deal could be worth roughly $250 million to Vitae, a small, development-stage pharmaceutical company based ...
Read More...

Boehringer Ingelheim and Vitae Pharmaceuticals Announce a Major Collaboration to Research and Develop Novel Treatments for Alzheimer`s disease

Drugs.com - 982 days ago
Companies to advance beta-secretase (BACE) inhibitors, which hold potential for slowing the progression of this devastating neurodegenerative disease Fort Washington/Pennsylvania and Ingelheim/Germany, 15 June 2009 - Boehringer Ingelheim and Vitae Pharmaceuticals, Inc., announced today that they have entered into a significant worldwide ...